Bulletin Updates

ARIL’s LOI pipeline, fluorine chemistry look strong: Is pharma leverage worthwhile? – 4 Jun 2026

Jun 04, 2026

Anupam Rasayan India delivered 65% revenue growth in FY26, backed by a Rs 14,646 crore letter-of-intent pipeline and the Jayhawk Fine Chemicals fluorine chemistry consolidation. But the announced acquisition of a 43-48% stake in Bliss GVS Pharma has triggered rating watch actions from both CRISIL and Ind-Ra — and the two agencies have reached different conclusions.

The full story is for subscribers. Log in to read it, or start a free trial.
Log in Start a free trial »